Announcement PDF ASX ANNOUNCEMENT 19 September 2024 Launching American Depositary Receipt program Sydney, Australia – 19 September 2024 -- Radiopharm Theranostics Limited (ASX:RAD) (“Company” or “Radiopharm”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the launch of a Level 1 American Depositary Receipt (“ADR”) program. Under the ADR program, shareholders of the Company may deposit their ordinary shares with Deutsche Bank Trust Company Americas, acting as Depositary of the ADR program, and receive American Depositary Shares (“ADSs”) representing ordinary shares of the Company. An American Depositary Share is a trading instrument denominated in US dollars that allows US investors to buy shares in non-US companies without the need for cross-border or crosscurrency transactions. Each ADS represents 200 ordinary shares of the Company. The establishment of the ADR program does not involve an offer of any new shares and no capital is being raised. The ADR program will complement the Company’s existing primary listing of ordinary shares on ASX. This strategic initiative represents a steppingstone to the Company’s proposed listing of ADSs on Nasdaq. The ADR program is part of a strategy to attract new US institutional and retail investors. However, given the ADSs are not currently listed on Nasdaq, they will initially trade in the US over-the-counter market under the ticker symbol RADTY. "We are excited about the establishment of an ADR program as it should attract new US investors. In addition, the ADR program will assist Radiopharm in completing its proposed Nasdaq listing that was announced on 26 July 2024," said Riccardo Canevari, CEO and Managing Director of Radiopharm. Beginning today, shareholders of the Company can deposit their ordinary shares and receive ADSs. For further information, please see “Frequently Asked Questions” below. US shareholders who participated in the Company’s recent placement would, however, receive ADSs that are restricted from trading for one year from the date of sale of the underlying ordinary shares, unless Radiopharm registers such shares prior to the end of the restrictive period. As discussed in Radiopharm’s announcement of 25 June 2024, if shareholders who purchased ordinary shares in Radiopharm’s recent placement do not deposit such ordinary shares in the ADR program, then they will not be entitled to any additional options if Radiopharm does not list on Nasdaq and register, as may be required under the US Securities Act of 1933, those ordinary shares by 31 December 2024. Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper. Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 ASX ANNOUNCEMENT 19 September 2024 For more information: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: rc@radiopharmtheranostics.com Matt Wright NWR Communications P: +61 451 896 420 E: matt@nwrcommunications.com.au Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm-theranostics/ Not an offer in the United States This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the US Securities Act or exempt from the registration requirements of the US Securities Act and applicable US state securities laws. ### Frequently Asked Questions What is an American Depositary Receipt (ADR)? An ADR is a negotiable US dollar denominated certificate representing ownership of shares in a non-US company. Holders of ADRs receive any dividends in US dollars and have the right to vote on shareholders resolutions via the depositary. The term ADR and ADS are often used interchangeably. ADRs were specifically designed to facilitate the purchase, holding and sale of non-US securities by US investors. How do you deposit your ordinary shares and receive ADSs You need to instruct your Australian broker to deposit the ordinary shares with the Custodian. The Custodian is BNP Paribas S.A. (ARBN 000 000 117), having its principal office at Level 6, 60 Castlereagh Street, Sydney NSW 2000, Australia. Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 ASX ANNOUNCEMENT 19 September 2024 Your Australian broker must effect the deposit of ordinary shares with the Custodian. The details of the Custodian account are: BNP Paribas S.A. CHESS Participant 01892 BIC: PARBAU2SLCC Account: 2020440001 Your Australian broker will need to provide ADS issuance instructions (which include your name, number of ordinary shares deposited, DTC number and account number) via an email to adr@db.com. Upon deposit of the ordinary shares, the Custodian will inform the depositary. The depositary, upon delivery to the depositary of such instructions (as well as any certification as it may require) and confirmation of deposit from the Custodian, then the depositary will issue the ADSs in accordance with your instructions. Who, or what, is the Custodian? The Custodian is the foreign correspondent bank of the depositary. with whom the company's underlying shares have been deposited. The custodian is usually situated in the same country as the company, but this is not always the case. On receipt of the company's underlying shares, the custodian will confirm such fact to the depositary and therefore allow it to issue the equivalent number of ADRs to the investor delivering the shares. What are the benefits of ADRs to US Investors? US investors may prefer to purchase ADSs rather than ordinary shares in the company's home market because ADSs trade, clear and settle in accordance with US market conventions. ADSs allow US investors to diversify into non-US securities relatively easily. Who is Radiopharm’s depositary for ADSs? Deutsche Bank Trust Company Americas is the depositary bank for Radiopharm’s ADR program. The depositary bank plays a key role in issuance as well as cancellation of ADSs. It also maintains the ADR holder register, distributes any dividends in US dollars and facilitates the exercise by the ADSs holders of their voting rights. What is the difference between a registered ADS holder and a beneficial ADS holder? A registered holder is the party whose name appears on the books of the depositary bank. The registered holder is considered the owner of record. A beneficial holder is the ultimate owner of the security, whose holdings are registered in a name other than their own. such as in the name of a broker, bank or nominee. Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889